---
title: "Lysergide (DT120) in Generalized anxiety disorder: Pharmacodynamics"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Pharmacodynamics. Topics: Thorough QT study of DT120 ODT: design and QT result, Thorough QT study of DT120 ODT: treatment-emergent adverse events, QTc interval after LSD with and without paroxetine in healthy participants, Vital signs across DT120 phase 1 and phase 2b studies, and 7 further topics. 11 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Thorough QT study of DT120 ODT: design and QT result

> “Phase 1 TQT (n = 59)”
> “Randomized, double-blind in healthy volunteers”
> “Single DT120: 100-μg ODT or 300-μg ODT”
> “DT120 was not shown to prolong the QT interval”
> “Dose increases beyond 100 μg showed similar AE profiles with no observed increased physiological or psychological safety risks”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="topic-2.1.2.6.2-2"></a>

### Thorough QT study of DT120 ODT: treatment-emergent adverse events

| Measure | Phase 1 TQT study, DT120 ODT (n = 58) |
| --- | --- |
| Any TEAE | “57 (98.3)” |
| TEAE leading to treatment withdrawal | “0” |
| Mild | “27 (46.6)” |
| Moderate | “27 (46.6)” |
| Severe | “3 (5.2)” |
| Any related TEAE | “57 (98.3)” |

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="topic-2.1.2.6.2-3"></a>

### QTc interval after LSD with and without paroxetine in healthy participants

> “LSD did not increase the QTc interval at its peak effect at 3.5 h after administration compared with 1 h before in either the paroxetine or placebo condition.”
> “There were no cases of QTc time increases >450 ms.”

Source: [Becker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12087691/)

<a id="topic-2.1.2.6.2-4"></a>

### Vital signs across DT120 phase 1 and phase 2b studies

> “Changes in vital signs were not clinically significant”
> “Clinically insignificant physiological effects”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="topic-2.1.2.6.2-5"></a>

### Heart rate, blood pressure, and body temperature by dose in healthy participants

> “The physiologic effects of LSD were moderate.”
> “None of the subjects had systolic blood pressure > 180 mmHg at any time.”
> “Peak heart rate > 100 beats/min was observed in 0%, 6%, 20%, and 25% of the subjects at 25, 50, 100, and 200 µg, respectively.”
> “Peak body temperature > 38° was observed in 0%, 11%, 7%, and 34% at 25, 50, 100, and 200 µg, respectively.”
> “Kidney and liver function parameters were unaltered.”

Source: [Holze et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9166834/)

> “LSD moderately increased blood pressure and heart rate.”

Source: [Holze et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8027607/)

<a id="topic-2.1.2.6.2-6"></a>

### Dose-response of subjective effects and ceiling at 100 µg in healthy participants

> “LSD showed dose-proportional pharmacokinetics and first-order elimination and dose-dependently induced subjective responses starting at the 25 µg dose.”
> “A ceiling effect was observed for good drug effects at 100 µg.”
> “The 200 µg dose of LSD induced greater ego dissolution than the 100 µg dose and induced significant anxiety.”
> “The average duration of subjective effects increased from 6.7 to 11 h with increasing doses of 25–200 µg.”

Source: [Holze et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8027607/)

> “Maximal ratings of > 50% good drug effects were reached in 37%, 91%, 96%, and 91% of the LSD administrations at 25, 50, 100, and 200 µg.”
> “Maximal ratings of > 50% bad drug effects were reached in 0%, 9%, 27%, 31% at 25, 50, 100, and 200 µg, respectively.”

Source: [Holze et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9166834/)

<a id="topic-2.1.2.6.2-7"></a>

### Concentration-effect relationship

> “A close relationship was observed between the LSD concentration and subjective response within subjects, with moderate counterclockwise hysteresis.”
> “Half-maximal effective concentration values were in the range of 1 ng/mL.”
> “The effects of LSD were related to changes in plasma concentrations over time, with no evidence of acute tolerance.”

Source: [Dolder et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5591798/)

<a id="topic-2.1.2.6.2-8"></a>

### Onset and peak of subjective effects: ODT versus capsule

> “Similar to PK profiles, the VAS scores showed an earlier onset of effects for MM120 ODT compared with capsules.”
> “Maximum drug effect VAS scores were reported at 3 and 4 hours post-dose for participants receiving MM120 ODT or capsules, respectively.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-2.1.2.6.2-9"></a>

### Time course of a dosing session described by the sponsor

> “The experience can generally be divided into 5 phases: onset (approximately 15-30 minutes after taking the dose), maximum effect (approximately 2 to 3 hours after dosing), plateau (approximately 3 to 5 hours after dosing), resolution (approximately 4 to 6 hours after dosing), and completion (approximately 6 to 10 hours after dosing).”

Source: [Definium Therapeutics LSD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/08/DFTX-FactSheet-LSD-080526.pdf)

<a id="topic-2.1.2.6.2-10"></a>

### Duration of subjective effects by dose in healthy participants

> “The subjective effects lasted (mean ± standard deviation) 8.2 ± 2.1 and 11.6 ± 1.7 h for the 100- and 200-µg LSD doses, respectively.”
> “Subjective peak effects were reached 2.8 and 2.5 h after administration of LSD 100 and 200 µg, respectively.”

Source: [Dolder et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5591798/)

> “Mean (±standard deviation) durations of subjective effects were 9.3 ± 3.2 and 11 ± 3.7 h, and maximal effects (any drug effects) were 77 ± 18% and 87 ± 13% after 85 and 170 μg of LSD, respectively.”

Source: [Holze et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37596682/)

<a id="topic-2.1.2.6.2-11"></a>

### Serotonin-2B receptor activity and valvulopathy: regulatory expectations

> “For psychedelic drugs with serotonin (5-HT) activity, the 5-HT2B receptor subtype has been linked to heart valvulopathy in humans”
> “sponsors should assess functional activity at the 5-HT2B receptor subtype”
> “Long-term exposure to drugs that have 5-HT2B agonism may induce cardiac valve stiffening.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
